William E. Rote - Aug 31, 2023 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Signature
/s/ Elizabeth E. Reed, Attorney-in-Fact
Stock symbol
TVTX
Transactions as of
Aug 31, 2023
Transactions value $
-$26,699
Form type
4
Date filed
9/5/2023, 08:13 PM
Previous filing
May 12, 2023
Next filing
Jan 25, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TVTX Common Stock Award $0 +3.3K +5.53% $0.00 63K Aug 31, 2023 Direct F1, F2
transaction TVTX Common Stock Sale -$26.7K -1.82K -2.88% $14.71 61.2K Sep 5, 2023 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On January 31, 2020, the reporting person was granted performance restricted stock units (PRSUs) covering 5,000 shares of the Issuer's common stock. On August 31, 2023, PRSUs vested upon the closing of the sale of the Company's bile acid portfolio following a modification approved by the Compensation Committee for a reduced number of shares to vest under PRSUs originally granted on January 31, 2020 that were to vest upon specified clinical or regulatory milestones related to the Company's bile acid portfolio.
F2 Includes 477 shares of the Issuer's common stock acquired by the reporting person on May 31, 2023 pursuant to an employee stock purchase program.
F3 The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.